Renaissance Technologies
ABCL icon

Renaissance Technologies’s AbCellera Biologics ABCL Stock Holding History

Renaissance Technologies’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78M Sell
990,929
-519,700
-34% -$2.54M 0.01% 1193
2026
Q1 		$5.27M Sell
1,510,629
-878,600
-37% -$3.16M 0.01% 1350
2025
Q4 		$8.17M Sell
2,389,229
-971,500
-29% -$4.34M 0.01% 1021
2025
Q3 		$16.9M Buy
3,360,729
+53,300
+2% +$235K 0.02% 811
2025
Q2 		$11.3M Buy
3,307,429
+413,400
+14% +$1.03M 0.02% 994
2025
Q1 		$6.45M Buy
2,894,029
+407,136
+16% +$1.17M 0.01% 1266
2024
Q4 		$7.29M Sell
2,486,893
-459,810
-16% -$1.28M 0.01% 1201
2024
Q3 		$7.66M Buy
2,946,703
+1,218,100
+70% +$3.38M 0.01% 1183
2024
Q2 		$5.12M Buy
1,728,603
+239,000
+16% +$904K 0.01% 1282
2024
Q1 		$6.75M Buy
1,489,603
+30,100
+2% +$154K 0.01% 1220
2023
Q4 		$8.33M Sell
1,459,503
-232,550
-14% -$1.08M 0.01% 1039
2023
Q3 		$7.78M Sell
1,692,053
-844,550
-33% -$5.14M 0.01% 1067
2023
Q2 		$16.4M Sell
2,536,603
-274,900
-10% -$1.88M 0.02% 769
2023
Q1 		$21.2M Buy
2,811,503
+689,100
+32% +$6.26M 0.03% 679
2022
Q4 		$21.5M Sell
2,122,403
-858,400
-29% -$9.92M 0.03% 676
2022
Q3 		$29.5M Sell
2,980,803
-1,055,500
-26% -$11.6M 0.04% 497
2022
Q2 		$43M Buy
4,036,303
+1,418,700
+54% +$12M 0.05% 404
2022
Q1 		$25.5M Buy
2,617,603
+2,078,400
+385% +$19.7M 0.03% 631
2021
Q4 		$7.71M Buy
539,203
+454,903
+540% +$6.9M 0.01% 1217
2021
Q3 		$1.69M Sell
84,300
-318,900
-79% -$5.64M ﹤0.01% 2219
2021
Q2 		$8.87M Buy
+403,200
New +$11.1M 0.01% 1261

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies's ABCL Position: Q2 2026 in Review

Renaissance Technologies reduced its AbCellera Biologics (ABCL) stake by 34% in Q2 2026, selling an estimated $2.54M and leaving 990,929 shares worth $7.78M. The position accounts for 0.01% of the portfolio, ranked #1193.

Renaissance Technologies first reported a position in ABCL in Q2 2021 and has held it in 21 quarters since. The position peaked at $43M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Renaissance Technologies held 990,929 shares of AbCellera Biologics worth $7.78M as of Q2 2026.
  • Renaissance Technologies sold 519,700 AbCellera Biologics shares in Q2 2026, an estimated $2.54M.
  • AbCellera Biologics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1193 holding.
  • Renaissance Technologies first reported a position in AbCellera Biologics in Q2 2021 and has held it in 21 quarters since.
  • Renaissance Technologies's AbCellera Biologics position peaked at $43M in Q2 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.